U.S. Pharma Stock News

VinFast’s delivery surge and what it could mean for VFS stock VinFast Auto (NasdaqGS:VFS) more than doubled its electric vehicle deliveries in 2025, topped its own guidance, and set a higher 2026 target, putting fresh attention on how these volumes line up with the current share price. See our latest analysis for VinFast Auto. The 26.33% year to date share price return, including a 28.23% gain over the last 90 days, suggests momentum has been building as investors react to the delivery beat...

Investors may be wondering whether Wingstop at around US$134.88 is starting to look interesting again, or if the stock’s valuation still feels out of step with its fundamentals. The share price has seen sharp moves recently, with a 17.8% decline over the last 7 days, an 18.8% decline over the last 30 days, and a 47.5% decline year to date. This will change how some investors think about both upside potential and risk. Recent coverage has focused on Wingstop’s position in the consumer...

Angi earnings shift draws investor focus Angi (ANGI) is in the spotlight after reporting first quarter 2026 results that showed sales of US$238.15 million, lower than the prior year, and a move from net income to a net loss. See our latest analysis for Angi. The earnings release and move to a quarterly net loss have coincided with a sharp reset in sentiment. Angi’s share price is at US$5.24 after a 90 day share price return of negative 55.78% and a 1 year total shareholder return of negative...

If you are wondering whether Ubiquiti at around US$926.69 is priced for perfection or still offers value, this article walks through what the current market price might be indicating. The stock has been volatile recently, with an 8.4% decline over the past week, a 10.7% return over 30 days, 63.6% year to date, 163.8% over 1 year, 435.7% over 3 years and 261.7% over 5 years. Recent attention on Ubiquiti has focused on its long term share price performance and what this means for current...

Why Azenta’s latest quarter is drawing attention Azenta (AZTA) has come under pressure after its second quarter report, which combined a US$149,083,000 goodwill and intangible asset impairment with a wider net loss, prompting investors to reassess the stock. See our latest analysis for Azenta. The earnings report and US$149.1m impairment have clearly shifted sentiment, with the 7 day share price return of negative 24.42% feeding into a year to date share price return of negative 44.38% and a...

Why Ingersoll Rand (IR) is on investors’ radar Ingersoll Rand (IR) has drawn investor attention after a period of mixed share performance, with the stock showing negative returns over the past week, month and past 3 months despite positive multi year total returns. See our latest analysis for Ingersoll Rand. At a share price of US$77.50, Ingersoll Rand’s short term share price return has been weak, with a 21.32% 3 month decline. However, the 3 year total shareholder return of 34.14% reflects...

In early May 2026, Harley-Davidson reported first-quarter net income of about US$24.77 million, sharply lower than a year earlier, as tariffs and higher costs compressed margins even while revenue of roughly US$1.17 billion exceeded analyst expectations and retail motorcycle sales rose, especially in North America. At the same time, management launched its "Back to the Bricks" turnaround plan, aiming to boost profitability through more affordable, rider-focused models, tighter dealer...

Unsurprisingly, Ambitions Enterprise Management Co. L.L.C's ( NASDAQ:AHMA ) stock price was strong on the back of its...

Bitdeer Technologies Group's ( NASDAQ:BTDR ) stock was strong after they recently reported robust earnings. However...

For investors wondering whether Bristol-Myers Squibb at around US$56.25 is offering value or risk at this point, this article breaks down what the current price might be indicating about the stock. The share price has had a mixed run, with a 7.2% loss over the last week and a 2.5% loss over the last month, but it is still up 5.2% year to date and 26.0% over the past year. Recent headlines around Bristol-Myers Squibb have focused on its position within the broader pharmaceuticals space and on...

Iovance Biotherapeutics (IOVA) opened Q1 2026 with revenue of US$71.4 million and a basic EPS loss of US$0.19, alongside net income excluding extra items at a loss of US$79.0 million. Over recent quarters, the company has seen revenue move from US$49.3 million in Q1 2025 to US$71.4 million in Q1 2026. Quarterly basic EPS losses ranged between US$0.18 and US$0.36 across that period, illustrating that top line scale is increasing while spending remains high and margins stay under pressure. See...

Wondering whether Alnylam Pharmaceuticals at around US$295.91 is offering fair value right now, or if the price is running ahead of the story? This article breaks down what the numbers suggest. The stock has seen mixed returns with a 4.4% decline over the last 7 days and a 7.4% decline over 30 days, but it is still up 14.5% over 1 year, 43.6% over 3 years and 122.6% over 5 years. Recent headlines have focused on Alnylam Pharmaceuticals' role in RNA interference based therapies and how its...

For investors considering whether Lyft at US$14.16 offers potential value or additional risk, this article explains what the current price might imply. Lyft's stock has returned 0.1% over the last week and 2.8% over the last month, while the year to date return is a 28.4% decline and the 1 year return is 8.9%. Taken together, these figures highlight changing views on its potential and risks. Recent coverage of Lyft has focused on how the company is positioned within transportation and ride...

In the past quarter, Air Products and Chemicals, Inc. reported second-quarter 2026 sales of US$3,171.8 million and net income of US$710.4 million, marking a return to profit from a very large net loss a year earlier. Beyond the headline earnings rebound, Air Products' largest-ever semiconductor investment with Samsung in South Korea underscores how its gas infrastructure is increasingly tied to advanced electronics manufacturing. We’ll now examine how this sharp earnings recovery, alongside...

Investors may be wondering whether Expedia Group at around US$252.79 is still offering value after a strong run, or whether the easier part of the opportunity has already passed. The stock has returned 1.8% over the last 7 days and 12.7% over the last 30 days, while the 1 year and 3 year returns are 50.8% and 180.0% respectively, with a year to date return showing a 10.7% decline. Recent headlines have focused on Expedia Group's position in online travel, including its product mix across...

Q1 earnings turnaround and shareholder returns in focus Ryan Specialty Holdings (RYAN) moved from a net loss to a net profit in the first quarter of 2026, with higher revenue, fresh buybacks, and an affirmed quarterly dividend drawing investor attention. See our latest analysis for Ryan Specialty Holdings. Despite the Q1 turnaround, momentum in Ryan Specialty Holdings' share price has been weak. A 1-day share price return of 7.89% contrasts with a 37.34% year to date share price decline and a...

WaFd, Inc. recently reported past Q2 2026 results showing net income of US$65.6 million on US$27.60 billion in assets, alongside an improved 2.81% net interest margin and continued dividends and share repurchases. The bank also highlighted strong credit protection with allowance for credit losses covering 163% of non-performing loans, underlining a focus on balance sheet resilience as it contends with deposit competition and higher funding and operating costs. Next, we’ll examine how WaFd’s...

NCR Voyix (VYX) Q1 2026 headline numbers NCR Voyix (VYX) opened 2026 with Q1 revenue of US$606 million and a basic EPS loss of US$0.04, setting a very different tone from the trailing twelve month EPS of US$0.30 that reflects a recent turn to profitability. Over recent quarters, revenue has moved between US$617 million in Q1 2025 and US$720 million in Q4 2025, while EPS has swung from a loss of US$0.17 in Q1 2025 to a profit of US$0.50 in Q4 2025 before slipping back into a small loss this...

Celldex Therapeutics (CLDX) stock snapshot Celldex Therapeutics (CLDX) has drawn fresh attention after recent trading moves, with the stock showing a 6.3% gain over the past month and a 40.2% return in the past 3 months. See our latest analysis for Celldex Therapeutics. Despite a 3.1% one day share price pullback to US$33.32, Celldex’s recent 30 day share price return of 6.3% and 90 day share price return of 40.2% point to building momentum. The 1 year total shareholder return of 70.7% shows...

Onterris (ONT) opened 2026 with Q1 revenue of US$168.5 million and a basic EPS loss of US$0.35, alongside net income excluding extra items of a US$12.7 million loss, putting fresh numbers behind a stock trading at US$17.45. The company has seen quarterly revenue move from US$177.8 million in Q1 2025 to US$189.1 million in Q4 2024 and US$168.5 million in Q1 2026, while basic EPS has swung from a US$0.64 loss in Q1 2025 to gains of US$0.48 and US$0.24 in mid 2025 before returning to recent...

Paycom Software (PAYC) opened 2026 with Q1 revenue of US$571.9 million and basic EPS of US$3.05, while trailing twelve month revenue stood at US$2.1 billion and EPS at US$8.61, setting a clear benchmark for its recent performance. Over recent quarters, the company has seen revenue move from US$530.5 million in Q1 2025 to US$571.9 million in Q1 2026, with basic EPS shifting from US$2.49 to US$3.05. This gives investors a straightforward view of how the top line and EPS have tracked together...

MGM Resorts International recently reported past first-quarter 2026 results, with revenue rising to US$4.45 billion while net income eased to US$125.14 million and diluted EPS from continuing operations slipped to US$0.48. Alongside these mixed earnings, MGM continued to return cash to shareholders through buybacks and saw digital and MGM China units drive record net revenues even as higher operating costs weighed on profitability. We’ll now examine how this combination of revenue growth and...

Vera Therapeutics, Inc. reported first-quarter 2026 results, posting a net loss of US$121.03 million, compared with US$51.69 million a year earlier, with basic and diluted loss per share from continuing operations rising to US$1.69 from US$0.81. The sharp year-on-year increase in both total net loss and per-share loss highlights how the company’s cost and investment profile has shifted over the past year. We’ll now explore how this widening quarterly net loss shapes Vera Therapeutics’...

If you are wondering whether Astec Industries at around US$53 is still sensibly priced or starting to look stretched, you are not alone. The stock has seen an 18.5% decline over the last 7 days and a 4.3% decline over the last 30 days, yet it is still up 18.8% year to date and 36.6% over the past 12 months. This can change how you think about both risk and opportunity. Recent news coverage has focused on how Astec Industries is positioned within the broader capital goods sector and how its...